

Nootropic drugs, other drugs that affect the nervous.
Pharmacodynamics:
The presence of tissue-specific signaling proteins and polypeptides — growth factors, differentiation factors of nerve cells — has a neuro-reparative effect by regulating the concentrations of the neurotransmitters pool, with inhibition of excitatory amino acids spilover. The drug activates secondary neuroprotection due to the stimulation of synaptogenesis, restoration of autophagy signals, improvement of tissue immunoregulation with inhibition of macrophage immunogenic cytotoxicity. At the same time, tissue-specific and systemic reparative effect of the drug is noted with the restoration of the regenerative and reparative potential of brain cells, a decrease in the number of damaged cells and the severity of perifocal edema in the penumbra zone (allows for significant reduction of the focus of necrosis of the brain tissue) with the restoration of microcirculation and general perfusion. Restoration and regulatory stimulation of various CNS compartments with systemic effects of growth factors, differentiation and signaling molecules reduces the recovery and rehabilitation of patients with damage to the central and peripheral nervous system of vascular genesis and restoration of motor, sensory and cognitive functions. The therapeutic effect usually develops 3-5 days after the start of drug administration.
Pharmacokinetics:
The complex composition of Cellec®, the active fraction of which consists of a balanced and stable mixture of biologically active proteins and polypeptides with a total polyfunctional effect, does not allow for the usual pharmacokinetic analysis of individual components.
Cerebrovascular diseases
- acute disorders of cerebral circulation in acute and early rehabilitation
the period of the disease as part of complex therapy.
Composition per 1 ml:
Active substance: Cellex substance-solution (frozen in terms of protein * 0.100 mg
Auxiliary substance:
Glycine - 3.75 mg
Sodium hydrophosphate dihydrate - 2.99 mg
Sodium dihydrogen phosphate monohydrate - 0.47mg
Sodium chloride - 5.85 mg
Water for injection to 1.0 ml
* - Composition per 1 ml:
Active substance:
Polypeptides from the brain of pig embryos, in terms of total protein 0.9 - 2.4 mg (nominal total protein content of 1.65 mg per 1 ml of the substance)
Glycine 3.75 mg, 0.1 M solution of disodium hydrogen phosphate to pH 7.8 (about 0.8 mg dry
substances), Sodium chloride 5.85 mg, Polysorbate-80 0.005 mg, Water purified to 1 ml.
No customer reviews for the moment.
For adults, the drug is prescribed in a dose of 0.1-0.2 mg 1 time per day subcutaneously for 10 days, depending on the severity of the patient's condition. If necessary, repeat the course after 10 days. Research on the use of the drug in pediatric practice has not been conducted.
Rules for the introduction of the solution: The drug is injected subcutaneously through a sterile syringe filter included in the kit. For the introduction of the required amount of Cellex® in the syringe, remove the needle, then put on the syringe a sterile syringe filter with a pore diameter of 0.22 μm. Take a new needle and put it on a sterile syringe filter. The drug is ready for use.
Allergic reactions can be observed in the form of unexpressed hyperemia at the injection site, hypersensitivity reactions (skin rash, itching, angioedema), low-grade fever, sleep disturbance, headache.
Epilepsy, manic psychosis, productive nonsense, delirium, age up to 18 years (due to
lack of clinical data).
When used together with psychostimulants and alcohol, psychomotor agitation and sleep disturbances are possible. Perhaps a decrease in the activity of means for anesthesia, tranquilizers, neuroleptics.
The lack of relevant studies does not allow the use of the drug in this contingent of patients.
It is prescribed with special care in cases of arterial hypertension of the malignant course in the decompensation stage; sympathetic-adrenal crises of the type of panic attacks; severe anxiety and depressive disorders. In pregnancy, the effect of the drug has not been studied. The drug does not contain prion infections and viruses.
Currently, cases of overdose Cellex® is not marked.
Studies and clinical trials of Cellex (Click to expand)